These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23152459)

  • 1. Omega-3 for patients with cardiovascular disease.
    Turgeon R; Janke F; Kolber MR
    Can Fam Physician; 2012 Nov; 58(11):1225. PubMed ID: 23152459
    [No Abstract]   [Full Text] [Related]  

  • 2. Omega-3 Fatty Acids and Cardiovascular Disease Prevention.
    Tomdio A; Ritchie M; Miller AC
    Am Fam Physician; 2019 Aug; 100(4):209-210. PubMed ID: 31414778
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized, controlled trials.
    Chen Q; Cheng LQ; Xiao TH; Zhang YX; Zhu M; Zhang R; Li K; Wang Y; Li Y
    Cardiovasc Drugs Ther; 2011 Jun; 25(3):259-65. PubMed ID: 21626218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of omega-3 polyunsaturated fatty acids in cardiovascular health.
    Barrett SJ
    Altern Ther Health Med; 2013; 19 Suppl 1():26-30. PubMed ID: 23981464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary cardiovascular prevention: omega-3 fatty acids ineffective.
    Prescrire Int; 2013 Sep; 22(141):218. PubMed ID: 24171221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Kwak SM; Myung SK; Lee YJ; Seo HG;
    Arch Intern Med; 2012 May; 172(9):686-94. PubMed ID: 22493407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 polyunsaturated fatty acids: is their future VITALized or REDUCEd?
    Gajos G
    Cardiovasc Res; 2019 May; 115(6):e58-e60. PubMed ID: 31077585
    [No Abstract]   [Full Text] [Related]  

  • 8. Omega-3 fatty acids and secondary prevention of cardiovascular disease-is it just a fish tale?: comment on “Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease”.
    Hu FB; Manson JE
    Arch Intern Med; 2012 May; 172(9):694-6. PubMed ID: 22493410
    [No Abstract]   [Full Text] [Related]  

  • 9. Meta-analysing randomised controlled trials with omega-3 fatty acids in cardiovascular disease.
    von Schacky C
    Evid Based Med; 2013 Aug; 18(4):e33. PubMed ID: 23161504
    [No Abstract]   [Full Text] [Related]  

  • 10. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
    Jaca A; Durão S; Harbron J
    S Afr Med J; 2020 Nov; 110(12):1158-1159. PubMed ID: 33403957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
    Harris WS; Dayspring TD; Moran TJ
    Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected].
    Casula M; Soranna D; Catapano AL; Corrao G
    Atheroscler Suppl; 2013 Aug; 14(2):243-51. PubMed ID: 23958480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?
    Kromhout D; Yasuda S; Geleijnse JM; Shimokawa H
    Eur Heart J; 2012 Feb; 33(4):436-43. PubMed ID: 21933782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials.
    Casula M; Olmastroni E; Gazzotti M; Galimberti F; Zambon A; Catapano AL
    Pharmacol Res; 2020 Oct; 160():105060. PubMed ID: 32634581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyunsaturated fatty acids and cardiovascular disease.
    Calzolari I; Fumagalli S; Marchionni N; Di Bari M
    Curr Pharm Des; 2009; 15(36):4094-102. PubMed ID: 20041811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on omega-3 PUFAs in heart failure.
    Aalbers J
    Cardiovasc J Afr; 2012 Jul; 23(6):345. PubMed ID: 22836158
    [No Abstract]   [Full Text] [Related]  

  • 17. Using omega-3 fatty acids in the practice of clinical lipidology.
    Brown WV; Bays H; Harris W; Miller M
    J Clin Lipidol; 2011; 5(6):424-33. PubMed ID: 22108145
    [No Abstract]   [Full Text] [Related]  

  • 18. Rebuttal to Aung et al, "Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals".
    von Schacky C
    Altern Ther Health Med; 2018 Mar; 24(2):8-9. PubMed ID: 29859508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The big ones that got away: omega-3 meta-analysis flawed by excluding the biggest fish oil trials.
    DiNicolantonio JJ; O'Keefe JH; Lavie CJ
    Arch Intern Med; 2012 Oct; 172(18):1427; author reply 1427-8. PubMed ID: 23045179
    [No Abstract]   [Full Text] [Related]  

  • 20. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review.
    Marik PE; Varon J
    Clin Cardiol; 2009 Jul; 32(7):365-72. PubMed ID: 19609891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.